SCHEMBL12083974

SCHEMBL12083974

CCc1cn(NC(=O)c2cnc(-c3cccc(F)c3)nc2C)c2cnccc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 6/20 0.51
▸ ROCK2 O75116 3/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.38
▸ CSNK2B P67870 1/20 0.38
▸ DGAT2 Q96PD7 2/20 0.37
▸ GRIN1 Q05586 1/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ MAP4K4 O95819 2/20 0.36
▸ WNT3A P56704 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ PIP4K2A P48426 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12084155 0.90 HPGDS (0.60) HPGDSROCK2CSNK1DCSNK2A2CSNK2B
SCHEMBL14313359 0.86 HPGDS (0.40) HPGDSROCK2CSNK1DCSNK2A2CSNK2B
SCHEMBL12084185 0.85 HPGDS (0.53) HPGDSCSNK1DMAP4K4WNT3AJAK2
SCHEMBL12083808 0.85 HPGDS (0.63) HPGDSROCK2CSNK1DCSNK2A2CSNK2B
SCHEMBL12084151 0.84 HPGDS (0.51) HPGDSCSNK1DGRIN2B
SCHEMBL3220594 0.83 HPGDS (0.52) HPGDSROCK2CSNK1DCSNK2A2CSNK2B
SCHEMBL12084130 0.82 HPGDS (0.61) HPGDSROCK2
SCHEMBL12083853 0.82 HPGDS (0.49) HPGDSCSNK1D
SCHEMBL12084004 0.81 HPGDS (0.55) HPGDSCSNK1DGRIN1GRIN2BWNT3A
SCHEMBL12084179 0.81 HPGDS (0.49) HPGDSCSNK1DGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 — — EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 HPGDS 10/4885ROCK2 3713/4885CSNK1D 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback